Search results
Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews
Apr 8, 2021 · Significant progress has been made in the treatment of ANCA-associated vasculitides (AAV), notably in granulomatosis with polyangiitis and microscopic polyangiitis. Over the past few years, many innovative studies have changed the way we now induce and maintain remission in AAV; achieving remission while limiting treatment toxicity is the key.
Mar 16, 2023 · Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods.
This Review focuses on diagnosis and treatment of PR3-ANCA-associated vasculitis and MPO-ANCA-associated vasculitis, and on the disease phenotypes of granulomatosis with polyangiitis and microscopic polyangiitis.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis comprises three syndromes, all with frequent respiratory manifestations. Studies indicate that ANCA specificity is more important for prognosis, relapse risk, response to therapy and outcomes than the specific diagnosis.
Apr 1, 2021 · From a therapeutic perspective, multiple targets have been identified for currently approved therapies and/or future directions, as treatment of ANCA-associated vasculitis becomes more precise and personalized, aiming to minimize the risks of therapy.
This includes new evidence on using lower doses of corticosteroids like rituximab and complement inhibition to treat ANCA vasculitis, as well as the use of avacopan as an alternative to glucocorticoids. The guideline also addresses therapies like plasma exchange for use in patients with advanced kidney disease.
Evaluate benefits and harms of reduced starting doses of GC (eg, 0.5 mg/day) compared with standard starting doses (1 mg/kg/day) in patients with different ANCA subtypes, severity stages and risk factors for adverse outcomes. Investigate optimal duration of therapy with GC.
May 22, 2023 · Describe the management options available for antineutrophilic cytoplasmic antibody (ANCA) associated vasculitides. Review some interprofessional team strategies for improving care coordination and communication to advance the care of patients with ANCA-associated vasculitides and improve outcomes.
In general, treatment for ANCA vasculitis involves 2 parts. The first part is called induction therapy , which is aimed at trying to get the disease controlled and into remission. Once the disease goes into remission, the second part of treatment is called maintenance therapy .
